Literature DB >> 19794096

A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34).

Satu Mustjoki, Sari Hernesniemi, Auvo Rauhala, Marketta Kähkönen, Anders Almqvist, Tuija Lundán, Kimmo Porkka.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19794096      PMCID： PMC2754971          DOI： 10.3324/haematol.2009.008094

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

1.  Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia.

Authors:  C Graux; J Cools; C Melotte; H Quentmeier; A Ferrando; R Levine; J R Vermeesch; M Stul; B Dutta; N Boeckx; A Bosly; P Heimann; A Uyttebroeck; N Mentens; R Somers; R A F MacLeod; H G Drexler; A T Look; D G Gilliland; L Michaux; P Vandenberghe; I Wlodarska; Peter Marynen; Anne Hagemeijer
Journal:  Nat Genet       Date:  2004-09-12       Impact factor: 38.330

2.  A new partner gene fused to ABL1 in a t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia.

Authors:  E De Braekeleer; N Douet-Guilbert; M-J Le Bris; C Berthou; F Morel; M De Braekeleer
Journal:  Leukemia       Date:  2007-05-31       Impact factor: 11.528

3.  Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia.

Authors:  W Deenik; H B Beverloo; S C P A M van der Poel-van de Luytgaarde; M M Wattel; J W J van Esser; P J M Valk; J J Cornelissen
Journal:  Leukemia       Date:  2008-11-06       Impact factor: 11.528

4.  Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32).

Authors:  Kim De Keersmaecker; Carlos Graux; Maria D Odero; Nicole Mentens; Riet Somers; Johan Maertens; Iwona Wlodarska; Peter Vandenberghe; Anne Hagemeijer; Peter Marynen; Jan Cools
Journal:  Blood       Date:  2005-02-15       Impact factor: 22.113

5.  The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase.

Authors:  S Roumiantsev; I E de Aos; L Varticovski; R L Ilaria; R A Van Etten
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

6.  The phosphorylation of CapZ-interacting protein (CapZIP) by stress-activated protein kinases triggers its dissociation from CapZ.

Authors:  Claire E Eyers; Helen McNeill; Axel Knebel; Nick Morrice; Simon J C Arthur; Ana Cuenda; Philip Cohen
Journal:  Biochem J       Date:  2005-07-01       Impact factor: 3.857

7.  Molecular cytogenetic and clinical findings in ETV6/ABL1-positive leukemia.

Authors:  H Van Limbergen; H B Beverloo; E van Drunen; A Janssens; K Hählen; B Poppe; N Van Roy; P Marynen; A De Paepe; R Slater; F Speleman
Journal:  Genes Chromosomes Cancer       Date:  2001-03       Impact factor: 5.006

8.  The t(1;9)(p34;q34) and t(8;12)(p11;q15) fuse pre-mRNA processing proteins SFPQ (PSF) and CPSF6 to ABL and FGFR1.

Authors:  Claire Hidalgo-Curtis; Andrew Chase; Milton Drachenberg; Mark W Roberts; Jerry Z Finkelstein; Sarah Mould; David Oscier; Nicholas C P Cross; Francis H Grand
Journal:  Genes Chromosomes Cancer       Date:  2008-05       Impact factor: 5.006

9.  Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.

Authors:  Oliver Ottmann; Hervé Dombret; Giovanni Martinelli; Bengt Simonsson; Francois Guilhot; Richard A Larson; Giovanna Rege-Cambrin; Jerald Radich; Andreas Hochhaus; Anne Marie Apanovitch; Ashwin Gollerkeri; Steven Coutre
Journal:  Blood       Date:  2007-05-11       Impact factor: 22.113
  9 in total
  7 in total

1.  RCSD1-ABL1-positive B lymphoblastic leukemia is sensitive to dexamethasone and tyrosine kinase inhibitors and rapidly evolves clonally by chromosomal translocations.

Authors:  Koiti Inokuchi; Satoshi Wakita; Tsuneaki Hirakawa; Hayato Tamai; Norio Yokose; Hiroki Yamaguchi; Kazuo Dan
Journal:  Int J Hematol       Date:  2011-08-24       Impact factor: 2.490

2.  Dasatinib and allogeneic stem cell transplantation enable sustained response in an elderly patient with RCSD1-ABL1-positive acute lymphoblastic leukemia.

Authors:  Miriam Frech; Lutz B Jehn; Kathleen Stabla; Stephan Mielke; Björn Steffen; Hermann Einsele; Stephan K Metzelder; Andreas Neubauer
Journal:  Haematologica       Date:  2017-01-05       Impact factor: 9.941

3.  Imatinib-induced long-term remission in a relapsed RCSD1-ABL1-positive acute lymphoblastic leukemia.

Authors:  Thomas Perwein; Sabine Strehl; Margit König; Herwig Lackner; Renate Panzer-Grümayer; Georg Mann; Andishe Attarbaschi; Ernst-Christian Urban; Oskar A Haas
Journal:  Haematologica       Date:  2016-04-28       Impact factor: 9.941

4.  Diagnostic evaluation of RNA sequencing for the detection of genetic abnormalities associated with Ph-like acute lymphoblastic leukemia (ALL).

Authors:  Kai Lee Yap; Larissa V Furtado; Kazuma Kiyotani; Emily Curran; Wendy Stock; Jennifer L McNeer; Sabah Kadri; Jeremy P Segal; Yusuke Nakamura; Michelle M Le Beau; Sandeep Gurbuxani; Gordana Raca
Journal:  Leuk Lymphoma       Date:  2016-11-17

5.  Increased expression of NuSAP in recurrent prostate cancer is mediated by E2F1.

Authors:  Z G Gulzar; J K McKenney; J D Brooks
Journal:  Oncogene       Date:  2012-02-20       Impact factor: 9.867

6.  RCSD1-ABL1 Translocation Associated with IKZF1 Gene Deletion in B-Cell Acute Lymphoblastic Leukemia.

Authors:  Shawana Kamran; Gordana Raca; Kamran Nazir
Journal:  Case Rep Hematol       Date:  2015-10-27

7.  Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia.

Authors:  Y Collette; T Prébet; A Goubard; J Adélaïde; R Castellano; N Carbuccia; S Garnier; A Guille; C Arnoulet; A Charbonier; M J Mozziconacci; D Birnbaum; M Chaffanet; N Vey
Journal:  Blood Cancer J       Date:  2015-03-13       Impact factor: 11.037
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.